{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Albuminuria&page=2", "query": { "condition": "Albuminuria", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Albuminuria&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T09:47:30.121Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07222917", "title": "A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease and Hypertension" ], "interventions": [ { "name": "Baxdrostat/dapagliflozin", "type": "DRUG" }, { "name": "Baxdrostat/Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2025-12-05", "completion_date": "2027-05-24", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 18, "location_summary": "Surprise, Arizona • Hollywood, Florida • Port Charlotte, Florida + 15 more", "locations": [ { "city": "Surprise", "state": "Arizona" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222917" }, { "nct_id": "NCT00625820", "title": "Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Disease", "Albuminuria" ], "interventions": [ { "name": "6R BH4", "type": "DRUG" }, { "name": "Vitamin C", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 17, "start_date": "2008-05", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2016-10-18", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00625820" }, { "nct_id": "NCT07547878", "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Lotensin", "type": "DRUG" }, { "name": "Capoten", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "Monopril", "type": "DRUG" }, { "name": "Lisinopril", "type": "DRUG" }, { "name": "Univasc", "type": "DRUG" }, { "name": "Aceon", "type": "DRUG" }, { "name": "Accupril", "type": "DRUG" }, { "name": "Altace", "type": "DRUG" }, { "name": "Mavik", "type": "DRUG" }, { "name": "Edarbi", "type": "DRUG" }, { "name": "Atacand", "type": "DRUG" }, { "name": "Avapro", "type": "DRUG" }, { "name": "Cozaar", "type": "DRUG" }, { "name": "Benicar", "type": "DRUG" }, { "name": "Micardis", "type": "DRUG" }, { "name": "Diovan", "type": "DRUG" }, { "name": "Invokana", "type": "DRUG" }, { "name": "Farxiga", "type": "DRUG" }, { "name": "Jardiance", "type": "DRUG" }, { "name": "Ertugliflozin", "type": "DRUG" }, { "name": "Brenzavvy", "type": "DRUG" }, { "name": "Sotagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 64, "start_date": "2026-04-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 1, "location_summary": "Temple, Texas", "locations": [ { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07547878" }, { "nct_id": "NCT00493727", "title": "Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes", "Proteinuria" ], "interventions": [ { "name": "N-acetylcysteine(Mucomyst)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 15, "start_date": "2006-09", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2008-05-19", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 1, "location_summary": "Dayton, Ohio", "locations": [ { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00493727" }, { "nct_id": "NCT05570305", "title": "Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Diseases" ], "interventions": [ { "name": "Zibotentan", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dapagliflozin and Zibotentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University Medical Center Groningen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2022-10-06", "completion_date": "2025-03-05", "has_results": false, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05570305" }, { "nct_id": "NCT00498537", "title": "Spironolactone for Reducing Proteinuria in Diabetic Nephropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetic Nephropathy" ], "interventions": [ { "name": "spironolactone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 30, "start_date": "2003-01", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2008-10-17", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 1, "location_summary": "Dayton, Ohio", "locations": [ { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00498537" }, { "nct_id": "NCT03015480", "title": "Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Kidney Disease", "Diabetes Mellitus", "Albuminuria" ], "interventions": [ { "name": "Remote counseling", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Geisinger Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 50, "start_date": "2017-02-13", "completion_date": "2018-11-25", "has_results": false, "last_update_posted_date": "2019-03-01", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 2, "location_summary": "Danville, Pennsylvania • Wilkes-Barre, Pennsylvania", "locations": [ { "city": "Danville", "state": "Pennsylvania" }, { "city": "Wilkes-Barre", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03015480" }, { "nct_id": "NCT01989754", "title": "A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2", "Albuminuria" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Canagliflozin, 100 mg", "type": "DRUG" }, { "name": "Canagliflozin, 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 5813, "start_date": "2014-01-16", "completion_date": "2017-02-23", "has_results": true, "last_update_posted_date": "2018-12-11", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 57, "location_summary": "Little Rock, Arkansas • Carmichael, California • Concord, California + 54 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Pismo Beach", "state": "California" }, { "city": "Roseville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01989754" }, { "nct_id": "NCT03029351", "title": "GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type2 Diabetes", "Kidney Diseases" ], "interventions": [ { "name": "Exenatide Extended Release for Inj Susp 2 MG", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 15, "start_date": "2017-01-10", "completion_date": "2019-07", "has_results": true, "last_update_posted_date": "2024-04-16", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 1, "location_summary": "Williamsville, New York", "locations": [ { "city": "Williamsville", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03029351" }, { "nct_id": "NCT03118739", "title": "Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperuricemia", "Albuminuria", "Type 2 Diabetes" ], "interventions": [ { "name": "Verinurad 9 mg+Febuxostat 80 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 60, "start_date": "2017-05-18", "completion_date": "2018-08-13", "has_results": true, "last_update_posted_date": "2020-01-10", "last_synced_at": "2026-05-22T09:47:30.121Z", "location_count": 18, "location_summary": "Canyon Country, California • Chula Vista, California • Corona, California + 12 more", "locations": [ { "city": "Canyon Country", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03118739" } ] }